NASDAQ:CADL

Candel Therapeutics (CADL) Stock Forecast, Price & News

$1.14

+0.01 (+0.88%)

(As of 09/21/2023 ET)

Compare

Today's Range: $1.12
▼
$1.22
50-Day Range: $1.05
▼
$1.30
52-Week Range: $0.98
▼
$3.59

Volume: 9,945 shs
Average Volume: 24,838 shs
Market Capitalization: $32.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Candel Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 689.5% Upside
$9.00 Price Target
Short Interest: Bearish
0.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.02) to ($0.87) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

672nd out of 965 stocks

Biological Products, Except Diagnostic Industry

108th out of 162 stocks

3.5

Analyst's Opinion

Consensus Rating
Candel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Candel Therapeutics has a forecasted upside of 689.5% from its current price of $1.14.
Amount of Analyst Coverage
Candel Therapeutics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.99% of the float of Candel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Candel Therapeutics has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Candel Therapeutics has recently increased by 1.17%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Candel Therapeutics does not currently pay a dividend.
Dividend Growth
Candel Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CADL.

0.6

News and Social Media Coverage

MarketBeat Follows
1 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Candel Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
44.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 18.22% of the stock of Candel Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Candel Therapeutics are expected to grow in the coming year, from ($1.02) to ($0.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Candel Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Candel Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Candel Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Candel Therapeutics (NASDAQ:CADL) Stock

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

CADL Price History

30 days | 90 days | 365 days | Advanced Chart

CADL Stock News Headlines

September 22, 2023 | americanbankingnews.com

Candel Therapeutics (NASDAQ:CADL) Shares Up 0.9%

September 6, 2023 | finance.yahoo.com

Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 22, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

August 10, 2023 | msn.com

Candel Therapeutics GAAP EPS of -$0.33

August 10, 2023 | finance.yahoo.com

Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

August 2, 2023 | finance.yahoo.com

Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

July 6, 2023 | msn.com

Candel Therapeutics (CADL) Price Target Decreased by 28.92% to 7.40

June 29, 2023 | benzinga.com

Candel Therapeutics Director Awarded $17K Worth of Stock Options

September 22, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

June 29, 2023 | benzinga.com

Candel Therapeutics Board Member Awarded $17K Worth of Stock Options

June 13, 2023 | finance.yahoo.com

Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

June 8, 2023 | finance.yahoo.com

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

June 5, 2023 | finance.yahoo.com

Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

May 22, 2023 | msn.com

HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation

May 22, 2023 | finance.yahoo.com

Favourable Signals For Candel Therapeutics: Numerous Insiders Acquired Stock

May 22, 2023 | markets.businessinsider.com

Candel Therapeutics (CADL) Receives a Buy from H.C. Wainwright

May 22, 2023 | finance.yahoo.com

Favourable Signals For Candel Therapeutics: Numerous Insiders Acquired Stock \

May 19, 2023 | tmcnet.com

Candel Therapeutics Announces New Data from Ongoing Phase

May 19, 2023 | msn.com

Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer

May 19, 2023 | finance.yahoo.com

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 16, 2023 | msn.com

BMO Capital Maintains Candel Therapeutics (CADL) Outperform Recommendation

May 12, 2023 | msn.com

Candel Therapeutics: Q1 Earnings Insights

May 11, 2023 | finance.yahoo.com

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 2, 2023 | finance.yahoo.com

Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO

April 17, 2023 | msn.com

Candel rallies 18% on FDA Fast Track tag for lead asset

April 17, 2023 | finance.yahoo.com

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer

March 31, 2023 | msn.com

Candel Therapeutics's Return On Capital Employed Insights

See More Headlines

Receive CADL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CADL Company Calendar

Last Earnings: 8/10/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CADL
CUSIP: N/A
CIK: 1841387
Web: www.candeltx.com
Phone: 617-916-5445
Fax: N/A
Employees: 76
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +689.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,790,000.00
Net Margins: N/A
Pretax Margin: -51,903.23%
Return on Equity: -75.60%
Return on Assets: -44.60%

Debt

Debt-to-Equity Ratio: 0.57
Current Ratio: 6.54
Quick Ratio: 6.54

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 253.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.65 per share
Price / Book: 0.69

Miscellaneous

Outstanding Shares: 28,920,000
Free Float: 16,022,000
Market Cap: $32.97 million
Optionable: Not Optionable
Beta: 0.32

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Paul-Peter Tak FMEDSCI (Age 63)
M.D., Ph.D., Pres, CEO & Director
Comp: $1.16M

Dr. Estuardo Aguilar-Cordova Inf. (Age 64)
M.D., Ph.D., Founder & Director
Comp: $35.08k

Dr. Seshu Tyagarajan Ph.D. (Age 56)
Chief Technical & Devel. Officer
Comp: $335.27k

Dr. Francesca Barone M.D. (Age 45)
Ph.D., Chief Scientific Officer
Comp: $518.91k

Mr. Jason A. Amello (Age 55)
CFO, Treasurer & Sec.

Ms. Ileen B. Winick
Chief People Officer

Ms. Susan Stewart J.D. (Age 62)
L.L.M., Chief Regulatory Officer

Dr. William Garrett Nichols M.D. (Age 54)
M.S., MS, Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CADL Stock - Frequently Asked Questions

Should I buy or sell Candel Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Candel Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CADL shares.
View CADL analyst ratings or view top-rated stocks.
What is Candel Therapeutics' stock price forecast for 2023?: 2 Wall Street analysts have issued 12 month target prices for Candel Therapeutics' stock. Their CADL share price forecasts range from $7.00 to $11.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 689.5% from the stock's current price.
View analysts price targets for CADL or view top-rated stocks among Wall Street analysts.
How have CADL shares performed in 2023?: Candel Therapeutics' stock was trading at $1.79 at the beginning of the year. Since then, CADL shares have decreased by 36.3% and is now trading at $1.14.
View the best growth stocks for 2023 here.
When is Candel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our CADL earnings forecast.
How were Candel Therapeutics' earnings last quarter?: Candel Therapeutics, Inc. (NASDAQ:CADL) released its earnings results on Thursday, August, 10th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.10.
When did Candel Therapeutics IPO?: (CADL) raised $72 million in an initial public offering on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

What is Candel Therapeutics' stock symbol?: Candel Therapeutics trades on the NASDAQ under the ticker symbol "CADL."
Who are Candel Therapeutics' major shareholders?: Candel Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Citigroup Inc. (0.41%). Insiders that own company stock include Francesca Barone, Jason Amello, Joseph C Papa, Paul Peter Tak and Seshu Tyagarajan.
View institutional ownership trends.
How do I buy shares of Candel Therapeutics?: Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Candel Therapeutics' stock price today?: One share of CADL stock can currently be purchased for approximately $1.14.
How much money does Candel Therapeutics make?: Candel Therapeutics (NASDAQ:CADL) has a market capitalization of $32.97 million and generates $130,000.00 in revenue each year. The company earns $-18,790,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.
How can I contact Candel Therapeutics?: The official website for the company is www.candeltx.com. The company can be reached via phone at 617-916-5445 or via email at investors@candeltx.com.

This page (NASDAQ:CADL) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial